Cytoville

Cytoville is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of next-generation cell therapies for solid tumors. The company utilizes its proprietary "Super-CAR" platform to engineer CAR-T cells with enhanced persistence and efficacy within the immunosuppressive tumor microenvironment. Cytoville's lead programs target high-unmet-need indications such as hepatocellular carcinoma and gastric cancer, focusing on antigens like GPC3 and Claudin 18.2. By integrating advanced cell engineering with deep biological insights, the company aims to overcome the traditional limitations of cell therapy in treating solid malignancies. Cytoville is backed by leading venture capital firms and led by a team of experienced biopharmaceutical professionals.